ORIGINAL ARTICLE

Psychological distress is highly prevalent in inflammatory bowel disease: A survey of psychological needs and attitudes

Antonina Mikocka-Walus,* Wayne Massuger,† Simon R Knowles,‡ Gregory T Moore,§ Stephanie Buckton,∥ Paul Pavli,¶ Leanne Raven,** Jane M Andrews††

*School of Psychology, Deakin University, †Crohn’s & Colitis Australia, ‡School of Health Sciences, Swinburne University of Technology, §Department of Gastroenterology, Monash Medical Centre, ¶School of Clinical Sciences, Monash University, ∥Department of Gastroenterology, St Vincent Hospital, Melbourne, Victoria, ‡‡Department of Gastroenterology, Sunshine Coast University Hospital, Sunshine Coast, ††Faculty of Science, Health and Engineering, University of Sunshine Coast, Sippy Downs, Queensland, ‡§Department of Gastroenterology, Canberra Hospital, Canberra, Australian Capital Territory and §§IBD Service, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Key words
distress, inflammatory bowel disease, psychological services.

Accepted for publication 13 July 2019.

Correspondence
Antonina Mikocka-Walus, School of Psychology, Deakin University, 221 Burwood Highway, Burwood, Vic. 3128, Australia.
Email: mikocka@deakin.edu.au

Declaration of conflict of interest: This work was supported by unrestricted educational grants from Ferring Pharmaceuticals, Takeda Pharmaceuticals Australia, and Janssen Australia and New Zealand awarded to Crohn’s & Colitis Australia, a not-for-profit patient support group. We do not have conflicts of interest in relation to the present study; however, here is the list of our conflicts of interests outside this work: Antonina Mikocka-Walus has served as an educational speaker for Janssen and Ferring. Simon R Knowles has served as a consultant for AbbVie, Janssen, Orphan, MSD, Pfizer, Shire, and Takeda. He received speaker’s fees from AbbVie, Ferring, Janssen, Orphan, Roche, Shire, and Takeda. He received research and educational support from AbbVie, Janssen, Shire, and Takeda. Stephanie Buckton has served on the advisory boards of Janssen and Abbvie and received education grants from Takeda, Shire, Janssen, and Abbvie. Jane M Andrews has served as a consultant for Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, Cellegene, Ferring, Gilead, Hospira, Immunic, Janssen, MSD, Nestle, Pfizer, Shire, Takeda, and Vifor.

Funding support: Ferring, Janssen Australia and New Zealand; Takeda Pharmaceuticals Australia

Abstract

Background and Aim: Data on patient needs and access to psychological services in inflammatory bowel disease (IBD) are scarce. This study aimed to describe the levels of distress and the needs, attitudes, and access to psychological services for people within Australia against established Australian IBD Standards.

Methods: An online cross-sectional survey was conducted with Australians ≥16 years old recruited via Crohn’s & Colitis Australia membership, public and private clinics, and the Royal Flying Doctor Service. K10 was used to measure psychological distress. The Chi-square test was used to compare those with and without distress on key variables.

Results: Overall, 731 respondents provided complete data (71.5% female, mean age 46.5 years). Overall, 50% of respondents reported distress; only 15.2% were currently seeing a mental health practitioner; only 16.1% were asked about their mental health by their IBD specialist or IBD nurse; and only 12.2% reported access to a mental health practitioner as part of their IBD service. Those with psychological distress were significantly less satisfied with their IBD care; more commonly hospitalized; had an active disease, fistula or perianal disease, pain, or fatigue; and were receiving steroids, opioids, or antidepressants (all *P < 0.05). As many as 68.2% of those with severe distress were not seeing a mental health practitioner.

Conclusions: The integrated biopsychosocial model of health care, with regular mental health screening and good access to mental health professionals, is requested by people living with IBD to improve their outcomes.
Introduction

Inflammatory bowel disease (IBD) affects 5 million people around the world, with an estimated 85,000 Australians having Crohn’s disease, ulcerative colitis, or indeterminate colitis. People living with IBD suffer from chronic pain, frequent loose bowel movements, weight loss, anemia, and fatigue, significantly impairing their everyday functioning and costing the Australian public $380 million in productivity losses and a further $2.7 billion associated with the management of IBD each year.1

IBD is increasingly considered a disorder of the brain–gut axis, where the gut’s health is affected by the brain’s health and vice versa. For example, it is now well established that, when a person suffers from IBD, they are at a higher risk of developing anxiety and/or depression2,3 and having poorer quality of life3,4 than the healthy population. The bidirectional links between mental and physical health in IBD have also been established5: Baseline IBD activity is associated with a nearly sixfold increase in the risk of anxiety over a period of 2 years, while anxious patients in IBD remission at baseline have a greater need for steroids, escalation of therapy, or IBD flare over time than those without anxiety. Moreover, the course of IBD is negatively affected by mental illness, resulting in more frequent flare ups,6,7 a more aggressive presentation,8 hospital readmissions,9 and increased risk of surgery.10

Despite the high prevalence of mental illness in IBD2 and the fact that the International IBD Guidelines11 and the Australian IBD Standards (Standard A: High Quality Clinical Care)12 recommend regular screening for distress and collaboration with mental health-care specialists in IBD management, recent studies demonstrated that only a fraction of patients reporting anxiety and depression receive the psychological or psychiatric help they need.13,14 Of interest, gender, education, perceived disease activity, and severity of psychological distress did not influence people’s likelihood of using mental health services; however, income did, with those with lower income more willing to engage.14

Data on patient needs and access to psychological services in IBD are scarce. A national audit of IBD hospital care found a major gap in the access to multidisciplinary services, including psychology support,15,16 but the data for mental health services outside inpatient care are lacking. The present survey was designed to describe the levels of distress in people with IBD, as well as the needs, attitudes, and access to psychological services for people with IBD in Australia against established Australian IBD Standards,12 which recommend psychological screening for all IBD patients, access to mental health services for inpatient assessment, and treatment and coordination of psychological treatment with primary care mental health services (Standard A13).

Methods

Design. The data for this study are derived from a large Australia-wide online survey of quality of health care for people with IBD. This study focused on comparing patient experience of health services with the Australian IBD Standards 2016.12 The full methods are presented elsewhere.17

Participants. People diagnosed with Crohn’s disease, ulcerative colitis, or indeterminate colitis (self-reported) who were aged 16 years or older were recruited via Crohn’s & Colitis Australia membership, public and private medical clinics throughout Australia, and the Royal Flying Doctor Service.

Measures. In addition to the demographics, disease activity, and the quality of care measures previously described,17 psychological distress was also measured using the Kessler Psychological Distress Scale (K10). K1018 is a simple measure of psychological distress using a 5-point Likert scale. The maximum score is 50, indicating severe distress; the minimum score is 10, indicating no distress.

Analysis. Data were collected using Qualtrics and analyzed using SPSS Statistics for Windows, Version 25.0; Armonk, NY, IBM Corp, USA. Descriptive statistics included means (SD) and frequencies (%). The Chi-square test was used to compare those with and without distress on key variables and present mental health engagement by distress level. A P value of less than 0.05 was considered significant.

Ethical approval. The study was approved by the Deakin University Human Research Ethics Committee and was performed in accordance with the Declaration of Helsinki. Participants gave informed consent before completing the survey.

Results

Overall, 731 people provided complete data: 71.5% female, 45.9% university educated, 65.1% married/de facto, 34.1% in full-time employment, and 57.6% with Crohn’s disease. Full demographics and clinical characteristics are presented elsewhere.17

Psychological care in IBD (Australian IBD Standard A13)

Level of distress. The mean level of distress for these respondents (K10 = 20.9) was within the mild distress category (20–24), while 51% of respondents reported good mental health (K10 score < 20), and 15% reported severe distress (K10 score ≥ 30) (Table 1).

Mental health practitioners. Overall, 15.2% of the respondents (n = 111) reported currently seeing a mental health practitioner, and for most of those respondents (73%), this was a psychologist (n = 81) (Table 1). The most common frequency of visits to a mental health practitioner was less often than once a month. Overall, 73% of those accessing mental health practitioners were satisfied with the treatment received.

Mental health as part of IBD management. Only 16.1% of respondents were asked about their mental health by their gastroenterologist or IBD nurse, and 56% of those not asked would have liked to be asked. Overall, 64.6% of the respondents would like their gastroenterologist or IBD nurse to ask about their mental health concerns.

Only 12.2% reported access to a mental health practitioner as part of their IBD service, with 58.9% agreeing or strongly agreeing that having access to a mental health expert...
### Table 1  Mental health characteristics and mental health care (Standard A13: Psychological care)

| K10, mean (SD) | IBD (n = 731) |
|---------------|---------------|
| K10†, n (%)   |               |
| Likely well (score 10–19) | 369 (50.5) |
| Likely mild distress (score 20–24) | 135 (18.5) |
| Likely moderate distress (score 25–29) | 96 (13.1) |
| Likely severe distress (score 30–50) | 110 (15) |
| Are you seeing anyone currently for any mental health issues/stress?‡ | |
| Yes | 111 (15.2) |
| Seeing a psychiatrist | 19 (2.6) |
| Seeing a psychologist | 81 (11.1) |
| Seeing a general practitioner | 45 (6.2) |
| Seeing a nurse | 1 (0.1) |
| Seeing a counselor | 8 (1.1) |
| Seeing a social worker | 2 (0.3) |
| Seeing CAM therapist | 2 (0.3) |
| If you are seeing a mental health expert, how often do you meet? | |
| Weekly (of the total of n = 111) | 9 (8.1) |
| Fortnightly (of the total of n = 111) | 17 (15.3) |
| Once a month (of the total of n = 111) | 36 (32.4) |
| Less often than once a month (of the total of n = 111) | 49 (44.1) |
| Are you satisfied with the treatment for your mental health issues? Yes (of the total of n = 111) | 81 (73) |
| While meeting with your gastroenterologist or IBD nurse in the past 12 months, have you been asked about any mental health concerns (even if not related to your IBD)?§ | |
| Yes | 322 (56) |
| Do you have access to a mental health expert (i.e. psychologist, psychiatrist) as part of your IBD service?¶ | |
| Yes | 89 (12.2) |
| I believe having access to a mental health expert (i.e. psychologist, psychiatrist) is an important part of managing my IBD†† | |
| Strongly agree | 229 (31.3) |
| Agree | 202 (27.6) |
| Neither agree nor disagree | 243 (33.2) |
| Disagree | 34 (4.7) |
| Strongly disagree | 13 (1.8) |
| I would like my gastroenterologist or IBD nurse to ask about any mental health concerns (even if not related to my IBD)¶¶ | |
| Yes | 472 (64.6) |
| I believe accessing mental health services (i.e. psychologist, psychiatrist) is easy to arrange†† | |
| Strongly agree | 53 (7.3) |
| Agree | 192 (26.3) |
| Neither agree nor disagree | 310 (42.4) |
| Disagree | 128 (17.5) |
| Strongly disagree | 38 (5.2) |
| I have found it easy (or would find it easy) to talk to my general practitioner about seeking mental health support¶¶ | |
| Strongly agree | 180 (24.6) |
| Agree | 258 (35.3) |
| Neither agree nor disagree | 193 (26.4) |
| Disagree | 74 (10.1) |
| Strongly disagree | 16 (2.2) |
| I have found it easy (or would find it easy) to talk to my gastroenterologist/IBD nurse about seeking mental health support¶¶ | |
| Strongly agree | 104 (14.2) |
| Agree | 212 (29) |
| Neither agree nor disagree | 252 (34.5) |
| Disagree | 123 (16.8) |
| Strongly disagree | 30 (4.1) |

†Missing n = 21 (2.9%).  
‡Missing n = 7 (1%).  
§Missing n = 8.  
¶Missing n = 156.  
¶¶Missing n = 10.

CAM, complementary and alternative medicine; IBD, inflammatory bowel disease.
(i.e. psychologist, psychiatrist) is an important part of managing their IBD. Only 33.6% of respondents believed that accessing mental health services (i.e. psychologist, psychiatrist) was easy to arrange. Nearly 60% would have found it easy to talk to their general practitioner about seeking mental health support, while 43.2% would have found it easy to discuss mental health with a gastroenterologist/IBD nurse.

**Poor outcomes are associated with distress.** Those with psychological distress were significantly less satisfied with their IBD care than those not distressed (Table 2). More commonly, participants having distress reported that they had an active disease (using patient-reported symptom-based instruments), fistula, or perianal disease and were taking steroids, opioids, or antidepressants (all $P < 0.05$).

Those distressed more commonly reported having been hospitalized in the previous year for their IBD and had more pain or fatigue. Those distressed would have liked to have been asked about their mental health by their gastroenterology team, less commonly had a plan of their IBD being reviewed annually, or reported that their care was explained to them.

Only 31.8% of those with severe distress were currently seeing a mental health practitioner (Table 3). Of those with severe distress not seeing a mental health professional ($n = 75$), 29 (39%) were taking antidepressants.

### Discussion

The Australian IBD Standards$^{12}$ detail the optimal quality of care in IBD; however, there are no studies examining how real-life health care compares to the Standards. The present study is the largest survey of mental health needs, attitudes, and access to mental health services in people living with IBD in Australia.$^{17}$

There is an important gap in mental health services for IBD patients in Australia: Only 12% of respondents had access to psychologists, while nearly 50% of respondents reported significant psychological distress. A previous Australian study$^{14}$ using the same measure of distress (K10) ($n = 336$) documented clinically significant levels in 52% of respondents. A national audit of IBD hospital care$^{5,16}$ identified that “mental health condition” was the most common comorbid condition and affected more than a quarter of hospitalized patients. Less than a quarter of these patients received psychological support in hospital. Similarly, in this study, only one-third of those with severe distress received mental health support. These statistics are in line with those of other western countries. In the United Kingdom, the provision of psychological support to IBD patients also remains at low levels, with only 12% of IBD services having access to clinical psychology via a defined referral pathway.$^{19}$ The current UK IBD Standards list access to psychologists as a particular challenge and area for improvement.$^{20}$

While poor access to mental health professionals is an obvious contributor to the low uptake of mental health services by people with IBD, it is presently unclear why those at high risk or with actual high severity of mental illness do not seek help, and more studies are needed in this area.$^{14}$

Of note, only 16% of this study’s respondents were asked about their mental health by their gastroenterologist or IBD nurse, and 56% of those not asked would have liked to be asked. For those who reported distress, 74% would have liked to be asked about their mental health by their gastroenterologist team. While gastroenterologists and IBD nurses are not mental health providers, the early detection of symptoms of anxiety and depression is essential to prevent the progression of mental illness and to reduce the risk of suicide. Of note, while good-quality data on

### Table 2 Distress versus no distress

|                | K10 no K10                      |
|----------------|--------------------------------|
|                | distress distress               |
| Are you satisfied with your IBD care? yes 314 (85.1)*** 217 (63.6) K10 |
| Manitoba index Active IBD 206 (55.8)*** 289 (84.8) K10 |
| Have a stoma 24 (6.5) 14 (4.1) K10 |
| Have a fistula 18 (4.9)* 28 (8.2) K10 |
| Have a perianal disease 17 (4.6)** 33 (9.7) K10 |
| Currently taking steroids 34 (9.2)*** 62 (18.2) K10 |
| Currently taking opioids 19 (5.2)*** 47 (13.8) K10 |
| Currently taking psychotropics 40 (10.9)*** 92 (27) K10 |
| Have you had an overnight hospital stay for your IBD in the last 12 months? yes 82 (22.2)*** 107 (31.4) K10 |
| Suffer from significant pain or discomfort? yes 99 (26.8)*** 216 (63.3) K10 |
| Often feel lacking in energy (fatigued) (by “often” we mean more than half of the time)? yes 155 (42)*** 287 (84.2) K10 |
| While meeting with your gastroenterologist or IBD nurse in the past 12 months, have you been asked about any mental health concerns (even if not related to your IBD)? no 299 (81) 266 (78) K10 |
| Is there a plan for your IBD to be reviewed at least once per year even if you are well? yes 318 (86.2)*** 266 (78) K10 |
| Has a member of your treatment team explained your care and treatment options? yes, completely 203 (55)*** 132 (38.7) K10 |

*$P < 0.05$. $**P < 0.01$. $***P < 0.001$.  

IBD, inflammatory bowel disease.
suicide in IBD in Australia are not available, a large-scale American study (n = 2,325,226) showed that 27% of people with IBD and depression reported suicidal ideation versus 12% of those without depression.21 A recent meta-analysis indicated that people with IBD may have increased risk of suicide.22 Psychological screening is an Australian standard of care for all people with IBD.12 Asking about mental health when a patient seeks help for IBD is an opportunity to identify and address distress. The integrated biopsychosocial model of health care, with regular mental health screening and good access to mental health professionals in gastroenterology clinics, is likely to improve patient outcomes and reduce health-care costs.23–28

Furthermore, in the present survey, psychological distress was associated with several important clinical parameters: active disease, hospitalization, presence of fistulas, perianal disease, pain, and fatigue and the current use of steroids, opioids, and psychotropics. This is in line with the findings of previous studies showing that poor mental health is associated with disease flares and a generally poorer IBD prognosis.7,8 Poor mental health has also been previously reported as a significant predictor of hospitalization,29 readmission,9 and increased risk of surgery10 in those with IBD. Pain, fatigue, and opioid use are also known to be associated with poor mental health in IBD.30–33 Therefore, our findings demonstrate that high rates of distress are likely to contribute to the burden of IBD at the personal and societal levels and translate into large costs of IBD care in Australia.1

The limitations of this survey have been previously discussed17 and include the following: its online nature, which precluded an objective assessment of IBD status and disease activity; a female-predominant sample of people aged 16 years and older excluded the pediatric population and limited the generalizability of its findings; and a low participation rate from people in remote areas.

In conclusion, psychological distress is prevalent in this Australian sample of people living with IBD, but access to mental health professionals in IBD clinics is limited despite the willingness of participants to discuss mental health and the association of distress with a variety of clinical parameters such as disease activity, hospitalizations, pain, fatigue, and opioid use. An integrated biopsychosocial model of health care, with regular mental health screening and good access to mental health professionals, will help people living with IBD improve their quality of life and other outcomes. Future studies should explore why many IBD patients with severe distress do not seek help and whether access to mental health professionals is the main reason for the low uptake of mental health services.

Acknowledgments

We especially thank the more than 1000 people living with inflammatory bowel disease who took the time to access this survey and provide important information for the improvement of the quality of care for those with IBD. Many contributed despite their health being affected by IBD at the time of survey.

References

1. PricewaterhouseCoopers. Improving Inflammatory Bowel Disease Care across Australia. Melbourne: Crohn’s & Colitis Australia, 2013.

2. Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm. Bowel Dis. 2016; 22: 752–62.

3. Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I. Inflamm. Bowel Dis. 2018; 24: 742–51.

4. Knowles SR, Keefer L, Wilding H, Hewitt C, Graff LA, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm. Bowel Dis. 2018; 24: 966–76.

5. Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC. Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease. Gastroenterology. 2018; 154: 1635–46.e5.

6. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am. J. Gastroenterol. 2010; 105: 1994–2002.

7. Mikocka-Walus A, Pittet V, Rossel JB, von Kanel R. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2016; 14: 829–35.e1.

8. Kochar B, Barnes EL, Long MD et al. Depression is associated with more aggressive inflammatory bowel disease. Am. J. Gastroenterol. 2018; 113: 80–5.

9. Barnes EL, Kochar B, Long MD et al. Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease in a nationwide database. Inflamm. Bowel Dis. 2017; 23: 875–81.

10. Ananthakrishnan AN, Gainer VS, Perez RG et al. Psychiatric comorbidity is associated with increased risk of surgery in Crohn’s disease. Aliment. Pharmacol. Ther. 2013; 37: 445–54.

11. Hauser W, Moser G, Klose P, Mikocka-Walus A. Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: a review. World J. Gastroenterol. 2014; 20: 3663–71.

12. CCA. Australian IBD standards: standards of healthcare for people with inflammatory bowel disease in Australia. Camberwell: Crohn’s & Colitis Australia, 2016.

13. Bennebroek Evertsz F, Thijssens NA, Stokkers PC et al. Do inflammatory bowel disease patients with anxiety and depressive symptoms receive the care they need? J. Crohns Colitis. 2012; 6: 68–76.

14. Knowles S, Andrews JM, Porter A. Predictors of impaired mental health and support seeking in adults with inflammatory bowel disease: an online survey. Gastroenterol. Nurs. 2018; 41: 38–46.
Distress in inflammatory bowel disease

A Mikocka-Walus et al.

15 CCA. Final Report of the First Audit of the Organisation and Provision of IBD Services in Australia. Camberwell: Crohn’s & Colitis Australia, 2016.
16 Massuger W, Moore GT, Andrews J et al. The Crohn’s & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia. Intern. Med. J. 2019; 49: 859–66.
17 Mikocka-Walus A, Massuger W, Knowles SR et al. Quality of care in inflammatory bowel disease: actual health service experiences fall short of the standards. J. Gastroenterol. Hepatol. 2019 (in press).
18 Andrews G, Slade T. Interpreting score on the Kessler psychological distress scale (K10). Aust. N. Z. J. Public Health. 2001; 25: 494–7.
19 RCP. National Audit Report of Inflammatory Bowel Disease Service Provision; Adult National Report. London: Royal College of Physicians, 2014.
20 TheIBDStandardsGroup. Standards for the Healthcare of People Who Have Inflammatory Bowel Disease (IBD). Cited 18 March 2014. Available from URL: http://www.ibdstandards.org.uk/uploaded_files/IBDstandards.pdf
21 Bhandari S, Larson ME, Kumar N, Stein D. Association of inflammatory bowel disease (IBD) with depressive symptoms in the United States population and independent predictors of depressive symptoms in an IBD population: a NHANES study. Gut Liver. 2017; 11: 512–9.
22 Zhang C, Byrne G, Lee T, Singer J, Giustini D, Bressler B. Incidence of suicide in inflammatory bowel disease: a systematic review and meta-analysis. J. Can. Assoc. Gastroenterol. 2018; 1: 107–14.
23 Mikocka-Walus A, Andrews JM, Rampton D, Goodhand J, van der Woude J, Bernstein CN. How can we improve models of care in inflammatory bowel disease? An international survey of IBD health professionals. J. Crohns Colitis. 2014; 8: 1668–74.
24 Mikocka-Walus A, Andrews JM, von Kanel R, Moser G. An improved model of care for inflammatory bowel disease (IBD). J. Crohns Colitis. 2013; 7: e120–1.
25 Mikocka-Walus A, Power M, Rook L, Robins G. What do participants of the Crohn’s and Colitis UK(CCUK) annual york walk think of their inflammatory bowel disease care? a short report on a survey. Gastroenterol. Nurs. 2018; 41: 59–64.
26 Mikocka-Walus AA, Andrews JM, Bernstein CN et al. Integrated models of care in managing inflammatory bowel disease: a discussion. Inflamm. Bowel Dis. 2012; 18: 1582–7.
27 Mikocka-Walus AA, Andrews JM, von Kanel R, Moser G. What are the implications of changing treatment delivery models for patients with inflammatory bowel disease: a discussion paper. Eur. J. Gastroenterol. Hepatol. 2013; 25: 393–8.
28 Mikocka-Walus AA, Turnbull D, Holtmann G, Andrews JM. An integrated model of care for inflammatory bowel disease sufferers in Australia: development and the effects of its implementation. Inflamm. Bowel Dis. 2012; 18: 1573–81.
29 van Langenberg DR, Lange K, Hetzel DJ, Holtmann GJ, Andrews JM. Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change. J. Gastroenterol. Hepatol. 2010; 25: 1250–8.
30 van Langenberg DR, Gibson PR. Systematic review: fatigue in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2010; 32: 131–43.
31 Graff LA, Vincent N, Walker JR et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm. Bowel Dis. 2011; 17: 1882–9.
32 Sweeney L, Moss-Morris R, Czuber-Dochan W, Meade L, Chumbley G, Norton C. Systematic review: psychosocial factors associated with pain in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2018; 47: 715–29.
33 Noureldin M, Higgins PDR, Govani SM et al. Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment. Pharmacol. Ther. 2019; 49: 74–83.